Cipla

Cipla ROE

The Return on Equity (ROE) of Cipla (CIPLA.NS) as of Oct 31, 2026 is 11.27 %. In the previous year, Return on Equity (ROE) was 16.90 % — a change of -33.35% (lower).

ROE

11.27 %

YoY

-33.35%

Last updated:

In 2026, Cipla's return on equity (ROE) was 11.27 %, a -33.35% increase from the 16.90 % ROE in the previous year.

The Cipla ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
10.18 INR
Jan 1, 2020
9.81 INR
Jan 1, 2021
13.12 INR
Jan 1, 2022
12.08 INR
Jan 1, 2023
11.97 INR
Jan 1, 2024
15.43 INR
Jan 1, 2025
16.90 INR
Jan 1, 2026
11.27 INR
The Cipla ROE history
YEARROEYoY
11.27 %-33.35%
16.90 %+9.53%
15.43 %+28.93%
11.97 %-0.87%
12.08 %-7.98%
13.12 %+33.75%
9.81 %-3.59%
10.18 %+2.66%
9.91 %+23.55%
8.02 %-32.06%
11.81 %+8.03%
10.93 %-14.96%
12.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cipla Stock analysis

What does Cipla do? Cipla Ltd is an Indian pharmaceutical company based in Mumbai. The company was founded in 1935 and is now one of the largest producers of generics worldwide. The name "Cipla" is an abbreviation for "Chemical, Industrial & Pharmaceutical Laboratories". Business Model: Cipla specializes in the production of high-quality generics. This means that they manufacture medication that has the same active ingredients as the original drugs. This allows them to offer medication at a significantly lower price. However, Cipla not only offers generics but also develops its own innovative medication. The focus is on therapy areas such as oncology, respiratory diseases, HIV/AIDS, diabetes, and cardiovascular diseases. Divisions: Cipla is divided into several divisions, including generics, specialty drugs, and biologics. The generics division is the company's core competence. Here, Cipla produces a variety of medications in different forms, such as tablets, capsules, suspensions, etc. The specialty drugs division focuses on innovative medications that are usually more expensive than generics. This includes medications for the treatment of cancer or autoimmune diseases. In the biologics division, Cipla produces biotechnology products based on the use of living cells. Products: Cipla offers a wide range of products, including medications for asthma, diabetes, hypertension, and infectious diseases. Some of the most well-known medications are Escitalopram (an antidepressant), Seroflo (an asthma medication), Tenofovir (an HIV medication), and Sorafenib (a cancer medication). The company continuously works on new products and invests heavily in research and development. Cipla also has a social responsibility. The company is involved in the fight against HIV/AIDS and produces life-saving medication for this disease at an affordable price. Furthermore, Cipla has launched a program called "Cipla Foundation" which works towards improving healthcare in developing countries. Overall, Cipla has achieved impressive growth and is now one of the most significant pharmaceutical companies worldwide. The company has proven that it is possible to offer high-quality medication at an affordable price and still be successful. Cipla is one of the most popular companies on Eulerpool.

ROE Details

Decoding Cipla's Return on Equity (ROE)

Cipla's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Cipla's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Cipla's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Cipla’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Cipla stock

Return on Equity (ROE) of Cipla is 11.27 % in 2026.

Return on Equity (ROE) of Cipla changed from 16.90 % to 11.27 %, representing a -33.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Cipla since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Cipla with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Cipla

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Cipla